arrow
M

Matthew Krebs

The University of Manchester and The Christie NHS Foundation Trust
H指数:49
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancer

西拉帕替尼(一种ATR激酶抑制剂)联合奥拉帕尼的安全性与有效性:在晚期实体瘤中的剂量递增研究及在晚期乳腺癌中的剂量扩展研究

2026-09-300
OAAI
Project Optimus for Radiation Therapy–Drug Combinations: Moving Beyond the Maximum Tolerated Dose

Project Optimus计划用于放射疗法-药物联合治疗:超越最大耐受剂量

2026-07-300
PRE
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC

I期研究:评估ceralasertib(一种ATR激酶抑制剂)联合durvalumab治疗复发或转移性NSCLC或HNSCC患者的疗效。

2026-03-310
OAAI
A first-in-human phase I clinical trial investigating the safety and efficacy of repeat dosing MSCTRAIL cell therapy in addition to chemotherapy and immunotherapy in patients with advanced lung cancer
2026-02-040
OAAI
Somatic evolution following cancer treatment in normal tissue

正常组织中癌症治疗后的体细胞进化

Nature
IF48.5
2025-12-100
OA
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial

德法替尼联合阿瓦替尼治疗实体瘤患者: 1期框架试验

2025-06-270
OAAI
Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study

Amivantamab在晚期NSCLC和MET外显子14跳跃突变参与者中的应用: CHRYSALIS研究的最终结果

2025-05-160
PREAI
Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer

颅内和系统性进展:在经铂类治疗的表皮生长因子受体外显子20插入突变型晚期非小细胞肺癌中接受阿曼曲单抗治疗

2025-05-100
PRE
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study
2024-11-011
PRE
Real-world (Rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France and Germany

法国和德国接受化疗(CT)治疗的激素受体阳性(HR+/HER2-)转移性乳腺癌(mBC)患者的真实世界(Rw)结局。

2024-09-010
PRE
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer

罗索替尼在ROS1融合阳性非小细胞肺癌中的应用

2024-01-1118
PRE
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

基于人工智能的模型ANORAK改善肺腺癌的组织病理学分级

2024-01-102
OAAI